Manufacturer
14 recalls in our database name Allergan Sales, LLC as the manufacturing or recalling firm.
Of the 14 recalls from Allergan Sales, LLC we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2 (14%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Allergan recalls Keller Funnel 2 devices due to potential missing lubricating coating on breast implants, which may affect insertion. No injuries reported.
Allergan is voluntarily recalling 72 bottles of Combigan ophthalmic solution in Tennessee due to current Good Manufacturing Practice (cGMP) deviations.
Allergan is recalling 153,616 bottles of Lumigan (bimatoprost) 0.01% ophthalmic solution because the product failed impurities and degradation specifications.
Allergan is recalling 715,041 bottles of Combigan ophthalmic solution because the product failed impurities and degradation specifications.
Allergan is recalling 648 units of Blephamide ophthalmic ointment because stability testing showed impurities exceeding specifications.
Allergan is recalling 56,878 bottles of Lumigan (bimatoprost) 0.01% ophthalmic solution because the product failed impurities and degradation specifications.
Allergan Sales, LLC is recalling 17,112 tubes of Tazorac (tazarotene) Gel 0.05% because the product failed content uniformity specifications.
Allergan Sales, LLC is recalling Tazorac (tazarotene) Gel 0.05% because it failed content uniformity specifications. The recall covers 25,247 tubes distributed nationwide.
Allergan is recalling Tazorac (tazarotene) Gel 0.05% because the product failed content uniformity specifications. The recall covers 17,802 units distributed nationwide and in Puerto Rico.
Allergan Sales, LLC is recalling Tazorac (tazarotene) Gel 0.05% sample packs due to failed content uniformity specifications.
Allergan is recalling Refresh Lacri-Lube eye ointment because unscrewing the cap may introduce small black particles into the product.
Allergan is recalling specific lots of FML ophthalmic ointment because small black particles from the tube cap may be present in the product.
Allergan is recalling 337 tubes of Blephamide ophthalmic ointment because small black particles from the tube cap may be present in the product.
Allergan is recalling Refresh P.M. eye ointment because small black particles from the tube cap may have entered the product.